Objective: To investigate the significance of hedgehog signaling pathway in chemoradiotherapy sensitivity and its effect on the prognosis of esophageal squamous cell carcinoma. Methods: In the present study, we used the method of immunohistochemistry to examine the expression status of two hedgehog components, PTCH1 and glioma-associated oncogene GLI-1, in 100 pre-treated biopsy specimens of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Results: We find that high levels of PTCH1 and GLI-1 were detected in 76.0 and 72.0% of esophageal squamous cell carcinoma, respectively. Significant associations of high PTCH1 and GLI-1 expression with large tumor size (both P ¼ 0.01), locoregional progression (P ¼ 0.001 and 0.003, respectively) and the lack of complete response to chemoradiotherapy (P ¼ 0.008 and 0.01, respectively) were observed. Univariate analysis revealed that high PTCH1 and GLI-1 expression was associated with poor locoregional progression-free survival, distant progression-free survival and overall survival. Furthermore, esophageal squamous cell carcinoma patients with high PTCH1 and GLI-1 expression have the shorter survival time than the subgroups with negative and low PTCH1 and GLI-1 expression. In multivariate analysis, PTCH1 and GLI-1 expression status were both evaluated as independent prognostic factors for locoregional progression-free survival, distant progression-free survival and overall survival. Conclusions: These findings suggest an important role for the activation of hedgehog signaling in esophageal squamous cell carcinoma progression and that PTCH1 and GLI-1 expression may be significantly associated with esophageal squamous cell carcinoma resistance to chemoradiotherapy.
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC), an aggressive human malignancy worldwide with poor prognosis, is the major histological type of esophageal cancer in East Asian countries including Japan and China and in some parts of Europe. Most patients present with locally advanced disease, for which definitive chemoradiotherapy (CRT) could be considered as an important component of the therapeutic strategy for ESCC (1) . Despite the development of multimodality therapies including surgery, chemotherapy, radiotherapy and CRT, prognosis even of patients who underwent complete resection of their carcinomas remains poor (2) . At present, only the stage based on tumor -node -metastases (TNM) classification and primary complete response to CRT are widely accepted as prognostic factors (3) . However, the clinical outcomes of ESCC are heterogeneous. Even if the ESCC patients with the same clinical stage treated with the same regimen of CRT, the therapeutic effects are often different, probably attributable to the differences in biologic behavior of the tumors (4) . Thus, the identification of specific molecular markers that could serve as predictors for CRT response and prognostic factors in ESCC would be highly desirable and has long been sought. To date, the expression of some genes has been reported to be associated with CRT sensitivity and/or prognosis of ESCC, such as trimethylation of lysine 27 on histone H3 (5), clusterin (6) , epidermal growth factor receptor (7), cyclin D1 (8), Ki-67 (9), P53 (10) and human epidermal receptor-2 (11) . However, some of the results obtained by different studies remain conflicting, improved prognostic markers that can further stratify patient outcome are therefore needed.
The hedgehog signaling pathway plays a critical role in the development of various organs, including the neural tube, lung, gastrointestinal tract, pancreas and prostate (12 -14) . Hedgehog family ligands include Sonic hedgehog, Indian hedgehog and Desert hedgehog. In the absence of hedgehog ligand, Patched family receptors (PTCH1 and PTCH2) inhibit another membrane receptor Smoothened (SMO), which leads to the formation of cytoplasmic glioma-associated oncogene (GLI) degradation complex. Binding of hedgehog to PTCH1 or PTCH2 releases the SMO signal transducer from Patched-dependent suppression, which promotes the nuclear accumulation of fulllength GLI-1 and leads to GLI-dependent transcriptional activation of target genes, such as GLI-1, PTCH1, CCND2 and FOXL1 etc. Normally, this pathway regulates cell growth and differentiation during embryonic tissue patterning as well as adult tissue homeostasis and may, in particular, be important for the maintenance of stem cell compartments in certain epithelia (15) . Increased hedgehog signaling, e.g. in the skin, cerebellum, muscle, lung, digestive tract, pancreas and prostate, can lead to cancer. In addition, hedgehog signaling pathway activity is associated with tumor metastasis. Aberrant activation of this pathway has recently been reported in various human cancers, such as basal cell carcinoma, prostate cancer, pancreatic cancer, gastrointestinal malignancies and ovarian cancers (16 -19) . Isohata et al. (20) also reported that the mesenchymal gene expression of undifferentiated epithelial cells of the esophagus is maintained or strengthened in ESCC cells through hedgehog signaling and hedgehog signal block inhibited esophageal keratinocyte differentiation and ESCC cell invasion and growth. However, its significance in CRT sensitivity and its effect on the prognosis of ESCC are still unknown. In the present study, we used the method of immunohistochemistry (IHC) to examine the expression status of two hedgehog components, PTCH1 and GLI-1, in 100 pre-treated biopsy specimens of ESCC patients treated with definitive CRT.
PATIENTS AND METHODS

PATIENTS AND TISSUE SAMPLES
Prior informed consent was obtained from the patients for the collection of specimens in accordance with the guidelines of First Hospital of Nanjing Medical University, Huaian, Jiangsu, P.R. China, and the study protocols were approved by the Ethics Committee of First Hospital of Nanjing Medical University, Huaian, Jiangsu, P.R. China. All specimens were handled and made anonymous according to the ethical and legal standards.
One hundred ESCC patients treated with definitive CRT were consecutively selected from the Department of Radiotherapy, First Hospital of Nanjing Medical University, Huaian, Jiangsu, P.R. China. The cases selected were based on the availability of biopsy specimens and follow-up data. Patients with distant metastases except for supraclavicular or celiac lymph nodes, and those with previous treatments were excluded. All of the samples used in this study were endoscopic biopsy specimens obtained before CRT. The clinicopathological characteristics of the 100 patients studied are summarized in Table 1 .
CHEMORADIOTHERAPY
All patients received the same concurrent CRT with the cisplatin/5-fluorouracil regimen. Cisplatin was administered as an i.v. drip at a dose of 80 mg/m 2 on day 1; 5-fluorouracil 3 g/m 2 was administered as a continuous i.v. infusion for 48 h on days 1 -2. Two cycles of chemotherapy were done during radiotherapy at 4-week intervals. Radiotherapy was carried out using an 8 MV linear accelerator. Two-or threedimensional treatment plans using computed tomography scans were done. The initial treatment volume included the primary tumor with a radial margin of 1.5-2 cm and a proximal and distal margin of 3 -4 cm and enlarged lymph nodes. A total radiation dose of 60 -70 Gy (1.8 -2.0 Gy/fraction, 5 days/week) was delivered with a three-field technique, and the treatment field was reduced after 40-46 Gy.
EVALUATION AND FOLLOW-UP
The effect of CRT was evaluated clinically for primary lesions based on esophagography and computed tomography 4 weeks after CRT according to World Health Organization (WHO) criteria. The patients were followed every 3 months for the first year and then every 6 months for the next 2 years and finally annually. The diagnostic examinations consisted of esophagography, computed tomography, chest X-ray, abdominal ultrasonography and bone scan when necessary to detect recurrence and/or metastasis. Locoregional progression was defined as cases in which the primary tumor and regional enlarged lymph nodes were evaluated as disease progression after CRT or recurrence after complete response (6) . Distant progression was defined as a failure to control the distant metastatic lymph nodes and/or occurrence of a new distant metastasis (6) .
IHC ANALYSIS
The specimens were fixed in 10% neutral-buffered formalin and subsequently embedded in paraffin. The
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paraffin-embedded tissues were cut at 3 mm and stained following being dried on ProbeOn Plus (Fisher Scientific International, Hampton, NH, USA). Staining was done using avidin -biotin complex with a microprobe manual stainer (Fisher Scientific International). The slide to which a paraffin section was attached went through deparaffinization and hydration and was then treated with a solution of peroxidaseblocking reagent (Dako, Glostrup, Denmark) to exhaust endogenous peroxidase activity. It was put in citric acid solution and heated for 10 min in a microwave and then left at 
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Hedgehog signal activation in ESCC room temperature for 20 min to expose antigen hidden inside the tissue due to formalin fixation, and the process was repeated three times. To inhibit non-specific antigenantibody reactions possible in IHC staining, the reaction was done using a protein blocker (Research Genetics, Huntsville, AL, USA) for 5 min and the slide was washed thoroughly with water. The slides were incubated overnight with the primary antibodies against PTCH1 (Cat# 6149; Santa Cruz Biotech, Santa Cruz, CA, USA) and GLI-1 (Cat# C-18; Santa Cruz Biotech) at 48C. Secondary antibodies for the detection of primary antibodies were reacted for 10 min using anti-mouse IgG (Sigma, St Louis, MO, USA) to which biotin was attached, and then washed with buffer solution and reacted with horseradish peroxidase for 10 min. It was washed thoroughly with buffer solution; chromogen AEC (3-amino-9-ethylcarvazole; Zymed, San Francisco, CA, USA) was then applied and reddish brown response was examined. After hematoxylin contrast staining, the slide was enclosed with Universal Mount (Research Genetics) and examined. In each IHC run, negative controls were carried out by replacing the primary antibody with mouse IgG. Known immunostaining-positive slides were used as positive controls. Following a hematoxylin counterstaining, immunostaining was scored by two independent experienced pathologists, who were blinded to the clinicopathological parameters and clinical outcomes of the patients. The scores of the two pathologists were compared and any discrepant scores were trained through re-examining the stainings by both pathologists to achieve a consensus score. The number of positive-staining cells in 10 representative microscopic fields was counted and the percentage of positive cells was calculated. Given the homogenicity of the staining of the target proteins, tumor specimens were scored in a semi-quantitative manner based on the percentage of tumor cells that showed immunoreactivity. The criteria used for the assessment of PTCH1 and GLI-1 expression was: if more than 10% of the tumor cells were stained, protein expression was considered to be 'positive' (,10%, 0; 5 -50%, 1þ; 50 -90%, 2þ; and .90%, 3þ). To evaluate the reliability of the scoring method, all sections were reviewed three times.
STATISTICAL ANALYSIS
Thesoftware of SPSS version 16.0 for Windows (SPSS Inc., IL, USA) and SAS 9.1 (SAS Institute, Cary, NC, USA) was used for statistical analysis. Continuous variables were expressed as . The associations between protein expression and different clinical parameters were evaluated using Fisher's exact test or x 2 test. We used the Kaplan -Meier estimator and univariate Cox regression analysis to assess the marginal effect of each factor. The differences between groups were tested by log-rank analyses. The joint effect of different factors was assessed using multivariate Cox regression. Differences were considered statistically significant when P was ,0.05.
RESULTS
IHC EXPRESSION AND CELLULAR DISTRIBUTION OF PTCH1 AND GLI-1
The results of IHC of PTCH1 and GLI-1 are summarized in Table 1 . PTCH1 immunoreactivities were detected in 76 of 100 primary tumors (76.0%) and in 12 of 100 mucous membranes adjacent to cancers (12.0%). GLI-1 detected in ESCC and in mucous membrane adjacent to cancer was 72.0 and 20.0%, respectively. PTCH1 and GLI-1 proteins were, respectively, presenting a cytoplasmic and nuclear pattern of staining. The previous studies of Yoshikawa et al. (21) and Mori et al. (22) revealed that a nuclear staining pattern of Gli-1 in cancer cells of ESCC specimens is associated with early recurrence and poor prognosis. Therefore, we focused on nuclear staining of the surgical specimens in the present study. Cytoplasmic staining was also observed in the tumors, but we classified the tumors only according to the percentage of cells positive for nuclear staining. Representative immunostainings for PTCH1 and GLI-1 are illustrated in Fig. 1 . PTCH1 and GLI-1-positive rates in ESCC groups were significantly higher than those in mucous membrane adjacent to cancer (both P , 0.01).
CORRELATION BETWEEN CLINICOPATHOLOGICAL VARIABLES, PTCH1 AND GLI-1 EXPRESSION AND CRT RESPONSE
When the correlation between PTCH1 and GLI-1 expression and clinicopathological features was analyzed, a significant association between PTCH1 and GLI-1 expression and tumor size was observed (both P ¼ 0.01) ( Table 1 ). There were significant differences in PTCH1 and GLI-1 expression between locoregional progression groups and non-locoregional progression groups (for PTCH1: P ¼ 0.001; for GLI-1: 0.003; Table 1 ). The expression patterns of PTCH1 and GLI-1 were the factors that showed significant associations with CRT response, in which high PTCH1 and GLI-1 expression was observed more frequently in the non-CR group than in the CR group (both P , 0.001; Table 1 ). Within the CR group, the positive expression of PTCH1 [(6/8, 75.0%) versus (4/14, 28.6%), P , 0.001] and GLI-1 [(5/8, 62.5%) versus (3/14, 21.4%), P , 0.001] was found more frequently in recurrent cases (n ¼ 8) than in non-recurrent cases (n ¼ 14). No correlation was found between PTCH1 and GLI-1 expression and clinicopathological variables such as patient's age, sex, tumor grade, tumor location, T status, N status, M status and distant progression status (all P . 0.05).
According to Spearman's rank correlation analysis, we found that PTCH1 (P , 0.01, r ¼ 0.56, n ¼ 100) protein expression level determined by IHC staining was positively correlated with GLI-1 protein expression level.
CORRELATION OF PTCH1 AND GLI-1 EXPRESSION WITH ESCC PATIENT SURVIVAL
Of the 100 ESCC patients, none was lost to follow-up. The median observation period was 22.8 months (2.6 -82.9
Jpn J Clin Oncol 2011;41 (3) 389 months), with 45 local control failures, 32 distant progression and 69 cancer-related deaths. The median survival time was 23.6 months. In univariate analysis, both high expression of PTCH1 and GLI-1 were evaluated to correlate closely with poor locoregional progression-free survival (LPFS), short distant progression-free survival (DPFS) and overall survival (OS) times ( Fig. 2 and Table 2 ). Further analysis in the subgroups of different PTCH1 and GLI-1 expression status showed that ESCC patients with high PTCH1 and GLI-1expression have the shortest survival time, whereas those with low PTCH1 and GLI-1 expression have the best prognosis in LPFS, DPFS and OS ( Fig. 2 and Table 2 ). The Kaplan -Meier analysis also demonstrated a significant impact of certain clinicopathological prognostic parameters such as CRT response, T status, N status and M status on patient survival (Table 2) . No significant association was found between patient survival and other clinicopathological variables, including radiotherapy dose and receiving adjuvant chemotherapy or not (P . 0.05). Furthermore, the parameters that were significant in univariate analysis were further examined in multivariate analysis. The results showed that the expression patterns of PTCH1 and GLI-1 were evaluated as independent predictors of LPFS, DPFS and OS for ESCC patients treated with definitive CRT (Table 3) .
DISCUSSION
Since ESCC patients with the same TNM system and/or CRT response, which are the most important prognostic factors for clinical outcome in ESCC (3), often display considerable variability in disease progression and survival (4), the traditional grading system may have reached its limits in providing critical information influencing patient prognosis and treatment strategies. Recently, several molecular markers have been identified in the pathogenesis of ESCC which could be used as potential predictive and prognostic markers (10 -12) . However, little was reported on the fact that they were uniquely and directly responsible for ESCC. Consequently, there is a great need to identify more proteins specifically related to ESCC, which might allow a tailored multimodality approach with increased efficacy, and develop new targets for therapy and indicator for the diagnosis.
In this study, we examined the expression of PTCH1 and GLI-1 in 100 ESCC samples by IHC. The result showed that the stainings of PTCH1 and GLI-1 in ESCC were predominantly cytoplasmic and nuclear staining, respectively. This was consistent with previous studies, including that in which Mori et al. (22) used the antibody targeting the GLI-1 protein in an IHC study of the human ESCC cell lines, KYSE890, which yielded similar results. These data suggest that the observed expression patterns of PTCH1 and GLI-1 by IHC were general and genuine to be cytoplasmic and nuclear patterns. Interestingly, we also found that majority of the detected ESCC expressed PTCH1 and GLI-1, which had significant differences compared with those in mucous membrane adjacent to cancers. In addition, in our ESCC cohort, high PTCH1 and GLI-1 expression was found to correlate with large tumor size in ESCC. By way of IHC, we found that there was a definite correlation between expression of both PTCH1 and GLI-1 and development of ESCC. 
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Hedgehog signal activation in ESCC For the association of clinicopathological variables and ESCC response to CRT, we observed that the high expression levels of PTCH1 and GLI-1 were the only significant predictors of CRT resistance. These findings suggest a potential impact of PTCH1 and GLI-1 on the cellular responses to ionizing radiation and cytotoxic drugs in ESCC. It has been shown by Sims-Mourtada et al. (23) that the hedgehog signaling pathway was extensively activated in esophageal cancer xenografts and residual tumors after CRT and the temporal kinetics of hedgehog signaling preceded increases in proliferation biomarker expression and tumor size during tumor regrowth. They further showed that hedgehog pathway activity influences proliferation rates of esophageal cancer cell lines through up-regulation of the G1-cyclin-Rb axis. Additionally, they found that blocking hedgehog signaling enhanced radiation cytotoxicity of esophageal cancer cells. These data suggest that unregulated hedgehog signaling within tumors may promote a continuous state of tissue repair and clonogenic proliferation once the tumor volume is reduced after CRT, contributing to tumor repopulation. Although a role for hedgehog signaling has been established in the formation and maintenance of a number of tumors, including basal cell, prostate, breast and pancreatic carcinomas among others (16 -19) , our study is the first to examine PTCH1 and GLI-1 activation in the context of tumor repopulation after CRT and suggests that in addition to its reported roles in carcinogenesis and tumor maintenance, aberrant activation of the hedgehog pathway may contribute to tumor repopulation and treatment failure.
The most important finding of our study was the prognostic significance of PTCH1 and GLI-1 expression in ESCC. Strikingly, ESCC patients with high PTCH1 and GLI-1 expression have the shortest LPFS, DPFS and OS times among the subgroups of different PTCH1 and GLI-1 expression status. The sum of PTCH1 and GLI-1 expression in ESCC cells might reflect the overall ability of the host to produced PTCH1 and GLI-1 into the circulation, which may be able to protect these circulating cancer cells from death, thereby increasing the chance of tumor progression and metastasis. Similar results have also been reported in ovarian cancers and gastric carcinomas, in which PTCH1 and GLI-1 immunostainings in tumor tissue are reproducible variables that are significantly associated with adverse outcome. Our results also suggest that PTCH1 and GLI-1 activation is more important than the above-mentioned parameters in orientating tumor biology and prognosis after CRT. Indeed, post-operative adjuvant chemotherapy failed to improve the prognosis of patients with PTCH1 cytoplasmic-and Gli-1 nuclear-positive tumors. Any therapeutic intervention could not arrest the disease progression in association with hedgehog signal activation. These results suggest that hedgehog signal activation might promote cancer regrowth and progression after CRT and that subtle PTCH1 and GLI-1 activation after CRT is indicative of the emergence of 'more aggressive' cancer cells. The functional properties of such cells might be influenced through external signals, including those that can affect migratory potential and are mediated by further differentiated cancer cells and host stromal cells. The signals that can influence migratory potential are thought to result in highly aggressive cancer forms and thereby contribute to cancer recurrence.
In conclusion, in our study, we describe for the first time the role of cytoplasmic PTCH1 and nuclear GLI-1 in CRT sensitivity and its effect on the prognosis of ESCC patients treated with definitive CRT. Our results provide some evidence for the concept that high PTCH1 and GLI-1 expression may be important in the acquisition of a CRT-resistant phenotype, and most importantly, the expression of PTCH1 and GLI-1, as detected by IHC, may be useful prognostic biomarkers for poor survival of ESCC patients treated with definitive CRT.
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